-
Journal of Experimental Medicine: Developed a new generation of tumor-specific PD1 antibody-IL15 fusion protein immunotherapy drugs
Time of Update: 2022-10-25
Anti-PD-1-IL-15-R delivers IL-15-R through PD-1 cis, specifically binding to and activating PD-1+CD8+ T cells in tumors to exert anti-tumor function As a new method of tumor treatment that has developed rapidly in recent years, tumor immunotherapy has made the situation of tumor treatment new by mobilizing the body's own immune system to fight tumors.
-
The large-scale planting of traditional Chinese medicinal materials helps enrich the people and increase income and promotes rural revitalization
Time of Update: 2022-10-25
Zhangxian is located in the south-central part of Gansu Province, located in the transition zone of the West Qinling Mountains and the Loess Plateau, with an average altitude of more than 1,800 meters, which is suitable for the cultivation of traditional Chinese medicinal materials.
-
Will the eighth batch of collective procurement include biosimilars? 180 companies compete for the 10 billion market!
Time of Update: 2022-10-25
With the end of the seventh batch of collective procurement, the eighth batch of collective procurement has become a hot topic in the industry. Among them, the widely concerned "biological drug colle
-
More than a year after taking office, the CEO of this pharmaceutical company joined the "resignation army"!
Time of Update: 2022-10-25
On October 21, Ridge Pharma announced that Mr. Hua Fengmao applied to resign as a director, chief executive officer (CEO), special committee of the board of directors and subsidiaries of the company due to personal reasons.
-
Will tumor genetic testing be included in centralized procurement? The official reply is coming!
Time of Update: 2022-10-25
In addition, whether tumor genetic testing projects will be included in the procurement with quantity, the National Medical Insurance Administration said: "Tumor genetic testing is a medical service project, and according to the current policy, the basic medical services provided by public medical institutions are subject to government guidance prices.
-
Will the eighth batch of collective procurement include biosimilars? One article combs 180 enterprises such as Qilu, Cinda, and Chia Tai Tianqing to compete for the 10 billion market!
Time of Update: 2022-10-25
Arrows on the strings "National procurement" is poised to surge in the market of 10 billion The National Health Insurance Bureau said in its reply letter that at present, 6 batches of chemical drugs and 1 batch of biological drugs (insulin special) have been purchased in a centralized manner, and positive progress has been made.
-
2023 Shenzhen International Micro-environment Refrigeration and Heat Dissipation Technology Exhibition
Time of Update: 2022-10-25
2023 Shenzhen International Micro-environment Refrigeration and Heat Dissipation Technology Exhibition Shenzhen International Micro environment Cooling Technology Exhibition2023 Essential information
-
Domestic pharmaceutical companies are constantly ushering in new breakthroughs in the field of new anti-tumor drugs
Time of Update: 2022-10-25
On October 19, it was reported that the clinical trial application of anti-tumor bispecific antibody injection (SIM0348) submitted by Simcere Pharmaceutical has been accepted by the State Food and Drug Administration and is intended to be used to carry out clinical trials for the treatment of advanced malignant tumors.
-
Tailor-made [Cloud Interview] The exclusive appointment channel of the Visual Environment Club is now open
Time of Update: 2022-10-25
The 2022 FERC Autumn Exhibition, which will be held from November 8th to November 14th, will be held at the same time as the ECE Summit Forum, cloud interviews, PPT presentations, and new product launches, which is your favorite?
-
Let rare diseases not be rare, 67% of domestic rare disease drugs have been included in medical insurance
Time of Update: 2022-10-25
js?cdnversion='+~(-new Date()/36e5)]; According to reports, up to now, 2860 drugs have entered the national medical insurance directory, and 67% of the listed rare disease drugs in China are among them, which greatly reduces the drug burden of patients.
-
The innovation achievements of pharmaceutical companies have gradually emerged, and the sales of a number of new Chinese medicine drugs have grown steadily
Time of Update: 2022-10-25
The sales of three innovative patented traditional Chinese medicines, Tongxinluo capsules, Sansong Yangxin capsules and Qilang Qiangxin capsules, which are laid out by Yiling Pharmaceutical in the field of cardiovascular and cerebrovascular diseases, have also steadily increased in recent years, with compound growth rates of 9.
-
214 drugs were taken off the network, what happened?
Time of Update: 2022-10-25
【Pharmaceutical Network Industry News】Recently, the Shandong Provincial Public Resources Exchange Center issued a notice on the withdrawal of medical consumables and in vitro diagnostic reagent produc
-
Pharmaceutical companies raise funds frequently, and most of the funds are used for innovation and research and development
Time of Update: 2022-10-25
In this IPO of the Science and Technology Innovation Board, Baiduoan intends to raise 760 million yuan for medical catheter industrialization upgrade projects, R&D center construction projects, marketing service network and information construction projects, and supplementary working capital projects.
-
Local API companies continue to have good news, which is related to the approval of products and the passage of inspection
Time of Update: 2022-10-25
js?cdnversion='+~(-new Date()/36e5)]; Recently, Tonghe Pharmaceutical issued an announcement that the APIs mirabelon and rivaroxaban passed the drug GMP (Good Manufacturing Practice) compliance inspection.
js?cdnversion='+~(-new Date()/36e5)]; Recently, Tonghe Pharmaceutical issued an announcement that the APIs mirabelon and rivaroxaban passed the drug GMP (Good Manufacturing Practice) compliance inspection.
-
The rapid growth of new channel consumption will detonate the market for ginseng products!
Time of Update: 2022-10-25
Please pay attention to the selected video "Development Status and Trend Analysis of Ginseng Products in 2022" recently launched by the TCM Industry Big Data Platform of TNT-Cloud Map. The release of the "Healthy China 2030" Plan Outline in 2016 marked the elevation of "Healthy China" to a national strategy.
-
Under the tide of cooperation between pharmaceutical companies, new drug development is still the mainstream
Time of Update: 2022-10-25
On October 18, biotech company Ikena Oncology announced that it has entered into a clinical trial cooperation agreement with AstraZeneca to evaluate Tagrisso (osimertinib) and Ikena IK-930 as a treatment for patients with EGFR-mutated non-small cell lung cancer.
-
Products continue to be approved, and there are long-term development opportunities in China's API industry
Time of Update: 2022-10-25
Northeast Pharmaceutical recently reported that the company's acetyl-levocarnitine hydrochloride API has been approved by the Drug Review Center of the State Medical Products Administration, and has received the "Chemical API Marketing Application Approval Notice" approved and issued by the State Medical Products Administration.
-
China's first mRNA vaccine was approved in Indonesia, and nearshore protein will explain the vaccine for you
Time of Update: 2022-10-25
In addition to raw material supply, nearshore protein is also developing mRNA stock solution preparation and detection processes to provide customers with more comprehensive services.
In addition to raw material supply, nearshore protein is also developing mRNA stock solution preparation and detection processes to provide customers with more comprehensive services.
-
Observation of the third quarterly report: The pharmaceutical company's children's drug revenue increased, and its total revenue declined
Time of Update: 2022-10-25
However, from the perspective of product field division, the company's advantages in children's drug products initially appeared in the first three quarters of 2022, achieving operating income of 950 million yuan, a year-on-year increase of 17.
-
Biomedical M&A will be active in 2022, and local pharmaceutical companies will increase their mergers and acquisitions of overseas companies!
Time of Update: 2022-10-25
For example, in October, Kyushu Pharmaceutical announced that it had decided to change the 185 million yuan raised in the fundraising and investment project to acquire 100% of Sandoz Zhongshan Pharmaceutical Factory and increase its capital.
